CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

FDA Grants Priority Review to KTE-C19 for Non-Hodgkin Lymphoma

May 26th 2017

The FDA has granted a priority review to axicabtagene ciloleucel for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma.

Dr. Shah on Status of CAR T-cell Therapies in ALL

May 26th 2017

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Dr. Papa on Leukapheresis Manufacturing Approach in Head and Neck Cancer

May 18th 2017

Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses leukapheresis manufacturing approach in head and neck cancer.

Leonard Highlights Agents, Approaches in Pipeline for Hematologic Malignancies

May 10th 2017

John P. Leonard, MD, discusses advancements across hematologic malignancies and pivotal trial data he is anticipating at the 2017 ASCO Annual Meeting.

Kite Reports Cerebral Edema Death in ZUMA-1 CAR T-Cell Trial

May 9th 2017

The first cerebral edema death in the ZUMA-1 CAR T-cell therapy trial was disclosed today by Kite Pharma on a conference call with investors announcing the company’s first quarter financial results.

Juno Hopes to Cut Production of CAR T Cells to Just 2 Days

May 8th 2017

JUNO Therapeutics announced that it hopes to accelerate its process for developing CAR T cells from weeks to just 2 days.

Neelapu Hopeful FDA Will Approve Axicabtagene Ciloleucel for NHL

May 8th 2017

Sattva S. Neelapu, MD, discusses the ZUMA-1 trial and the potential impact of these results on patients with non-Hodgkin lymphoma.

Dr. Leonard on Emergence of CAR T-cell Therapy in Hematologic Cancers

May 5th 2017

John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the emergence and potential of chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Dr. Kumar on Potential of CAR T-Cell Therapy in Multiple Myeloma

May 2nd 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.

Dr. Papa on the Impact of CAR T Cell Trial in Head and Neck Cancer

April 27th 2017

Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses the impact of a recent study of chimeric antigen receptor (CAR) T cells in head and neck squamous cell carcinoma.

Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALL

April 21st 2017

Low disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.

Kite Unveils Novel BCMA-Directed CAR T-cell Therapy

April 21st 2017

A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.

CAR T-Cell Therapy Shows Potential in Head and Neck Cancer

April 19th 2017

Sophie Papa, MD, discusses the early-phase results and the logic behind studying CAR T-cell therapy in solid tumors, such as head and neck cancer.

Lead ZUMA-1 Researcher Highlights CAR T Cell Findings in NHL

April 12th 2017

Frederick L. Locke, MD, discusses the ZUMA-1 trial in non-Hodgkin lymphoma and the next steps going forward.

Dr. Papa on CAR T-Cell Therapy for Head and Neck Cancer

April 6th 2017

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

Expert Summarizes State of CAR T-Cell Therapy in Hematologic Malignancies

April 6th 2017

Alfred L. Garfall, MD, discusses the latest developments with CAR T-cell therapy in hematologic malignancies

CAR T Cell Functionality Correlates With Outcomes, Offering a Biomarker for Response

April 4th 2017

The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.

CAR T-Cell Response Rate Tops 80% in NHL Trial

April 4th 2017

Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.

Dr. Papa on Challenges of CAR T-Cell Therapy in Head and Neck Cancer

April 1st 2017

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

FDA Grants Priority Review to CTL019 for ALL

March 30th 2017

The FDA has granted a priority review designation to tisagenlecleucel-T as a treamtnet for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia, making it the first CAR T-cell therapy to enter regulatory review.